Addressing HCV Elimination Barriers in Italy: Health Care Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy
mediaposted on 2021-02-25, 15:18 authored by Adis journals on behalf of, Massimo Andreoni, Giovanni Di Perri, Marcello Persico, Andrea Marcellusi, Olivier Ethgen, Yuri Sanchez Gonzalez, Mark Bondin, Zhenzhen Zhang, Antonella De Michina, Rocco Cosimo Damiano Merolla, Antonio Craxì
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.